PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
Neurological & CognitiveInvestigational (Phase 2)C
ARA-290
Cibinetide
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 70
- Activity
- 100
Overall check-ins
Trackers & reports
Overview
About ARA-290
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
- Category
- Neurological & Cognitive
- Regulatory status
- Investigational (Phase 2)
- Also known as
- Cibinetide
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
4
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Sources (3)
- Wiki study page →Source
- Wiki study page →Source
PubMed
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014
- Wiki study page →Source
PubMed
The time to develop treatments for diabetic neuropathy
Rendell MS. Expert opinion on investigational drugs. 2021
Tools
Explore more
Explore
More ways to learn about ARA-290 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about ARA-290?
This page summarizes 6 anonymized self-reports from PeptIQ users who track ARA-290, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for ARA-290?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for ARA-290?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ARA-290 safe to use?
This wiki does not assess safety or recommend use. ARA-290 is listed as Investigational (Phase 2). Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ARA-290?
This wiki summarizes observational community reports and linked citations for ARA-290. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for ARA-290 for study-level context — not medical advice.
What is the legal status of ARA-290?
ARA-290 is listed in PeptIQ as Investigational (Phase 2). Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of ARA-290?
Safety data quality for ARA-290 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on ARA-290?
This page links 3 sources for ARA-290. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.